Percutaneous injection of sclerosant agents as an effective treatment for cystic malformations of the head and neck

• Published in: Oral and maxillofacial surgery 2024-06, Vol.28 (2), p.809-818
• Main Authors: Paladini, Ilaria, Schirò, Silvia, Ledda, Roberta Eufrasia, Leo, Ludovica, Milanese, Gianluca, Epifani, Enrico, Andreone, Andrea, Capurri, Giulia, Fantoni, Matteo, Gemignani, Andrea, Gritti, Alessandro, Sesenna, Enrico, Menozzi, Roberto
• Format: Article
• Language: English
• Subjects: Cysts; Medicine; Medicine & Public Health; Oral and Maxillofacial Surgery
• ISSN: 1865-1569; 1865-1550; 1865-1569
• DOI: 10.1007/s10006-024-01210-9

Purpose To evaluate the clinical and aesthetic outcome of percutaneous injection of sclerosant agents to treat head and neck cystic malformations (HNCM) and to assess their recurrence rate based on histology and site. Methods Fifty-four subjects (mean age 46 years) with HNCM treated by percutaneous injection of sclerosant agents between January and December 2017 were included. Imaging and clinical data before and after the procedure were collected. Quality of Life Index, Pain Visual Analogue Scale, and Aesthetic Scale scores were measured to assess clinical and aesthetic outcomes. A size reduction of ≥ 70% assessed through the visual scale was considered significant. Results Of the 54 HNCM, there were 26 (48%) lymphatic malformations (LM), 13 (24%) salivary epithelial duct cysts of the parotid gland, 12 (22%) salivary mucoceles, and 3 (5%) branchial cysts. A significant size reduction and a satisfactory clinical-aesthetic outcome were observed in all types of LM. The number of reinterventions was significantly associated with the number of lesions ( p < 0.001). The lowest number of interventions was observed in macrocystic lymphatic malformations (average of 1.2 interventions). All salivary epithelial duct cysts showed a significant reduction in size, a satisfactory clinical-aesthetic outcome, and an average of 1.16 interventions per patient. Mucoceles had a worse response, with only 3/14 patients showing a satisfactory and long-lasting clinical outcome (average of 1.16 interventions). Treatment of branchial cysts showed the worst outcome with a limited clinical response (3/3). Conclusion Percutaneous injection of sclerosant agents may be considered as a first-line treatment for LM and salivary epithelial duct cysts.